Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.7%. By the end of trading, BioMarin Pharmaceuticals rose 45 cents (1.2%) to $38.35 on average volume. Throughout the day, 1.6 million shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock ranged in a price between $37.69-$38.57 after having opened the day at $37.85 as compared to the previous trading day's close of $37.90. Other companies within the Drugs industry that increased today were:
), up 26.7%,
), up 17.8%,
), up 16%, and
), up 15.9%.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $4.78 billion and is part of the
sector. Shares are up 12.6% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.
TheStreet Ratings rates BioMarin Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.
- You can view the full BioMarin Ratings Report.
On the negative front,
), down 19.6%,
), down 12%,
), down 9.6%, and
), down 8.8%, were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.